

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – August 14, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.

- A. July 10, 2013 DUR Minutes – Vote
- B. July 10, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Le & Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.

- A. Medication Coverage Activity for July 2013
- B. Pharmacy Help Desk Activity for July 2013
- C. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

5. Action Item – Authorize Fulyzaq™ – See Appendix C.

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

6. Action Item – Vote to Prior Authorize Vecamyl™ – See Appendix D.

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

7. Action Item – Annual Review of ADHD Medications and 30 Day Notice to PA Quillivant XR™ – See Appendix E.

- A. Current Authorization Criteria
- B. Utilization of Stimulants
- C. Prior Authorization Review
- D. Market News and Updates
- E. Product Summary
- F. COP Recommendations
- G. Utilization Details
- H. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 8. Action Item – Annual Review of Atypical Antipsychotics Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization of Atypical Antipsychotics
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. Utilization Details
 - F. COP Recommendations
 - G. Utilization Details

Items to be presented by Kori Hammon, Dr. Muchmore, Chairman

- 9. 30 Day Notice to Prior Authorize Tysabri[®] – See Appendix G.**
 - A. Summary
 - B. Utilization of Tysabri[®]
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

- 10. 30 Day Notice to Prior Authorize Diclegis[®] – See Appendix H.**
 - A. Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 11. Questions Regarding Annual Review of Synagis[®] – See Appendix I.**
 - A. Current Authorization Criteria
 - B. Utilization of Synagis[®]
 - C. Prior Authorization Review
 - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 13. FDA and DEA Updates – See Appendix J.**

- 14. Future Business**

- A. Annual Reviews
- B. New Product Reviews

- 15. Adjournment**